|
Axtria Harnesses GenAI to Slash Timelines and Boost Accuracy in Clinical Study Reporting with Axtria Rapid CSR
Wednesday, February 12, 2025
GenAI-powered solution delivers clinical study reports in minutes with 30%-50% faster turnarounds, 90% ICH-E3-aligned accuracy, and substantial cost savings.
BERKELEY HEIGHTS, N.J., Feb. 4, 2025 /PRNewswire/ -- Axtria Inc., a global cloud software and data analytics company for the life sciences industry, announces groundbreaking advancements in its Clinical Solutions practice with the launch of Axtria Rapid CSR, an innovative use of Generative AI for the processing and automation of clinical study report (CSR) development. Axtria Rapid CSR has been trained and tested to reduce the generation of these reports by 30%-50% for most large-scale phase III clinical trials.
"We developed Axtria Rapid CSR to enhance efficiency in manual, error-prone tasks like interpreting clinical study data, deciphering complex tables and graphs, and analyzing annotated case report forms to rapidly develop an initial, complete CSR," said Luke Dunlap, Principal and Head of Clinical Solutions at Axtria. "We have seen significant advances in our ability to generate accurate medical writing, particularly in the areas of safety and efficacy where our solution draws critical inferences from multiple study data inputs, even for the most complex sections of a CSR."
Axtria Rapid CSR is capable of supporting studies of all sizes, from early-phase trials to post-surveillance. Watch a short video here.
-- What this Does: Axtria Rapid CSR transforms clinical study reporting
by streamlining the entire CSR authoring workflow, combining the
power of artificial intelligence with human expertise to deliver
superior results. This leverages multiple LLM approaches to consume
data from thousands of file formats, summarizing both structured and
unstructured source documents. Results adhere to ICH-E3 guidelines
for formatting requirements and can cross-reference multiple tables
to support a single summary across sections.
-- Impact it Delivers: Axtria Rapid CSR delivers data extraction and
interpretation with over 90% accuracy in completed experiments and
generates report sections in minutes, enabling quicker regulatory
submissions.
About Axtria's Clinical Solutions
Axtria's Clinical Solutions practice area drives value realization for life sciences companies through groundbreaking clinical innovations and measurable results. Our expertise lies in solving complex challenges in life sciences research and development through cutting-edge data science, generative AI, and advanced information management solutions. We specialize in modernizing clinical data workflows, enhancing clinical program management, and running late-phase investigations, leveraging proprietary technology accelerators to deliver measurable improvements in efficiency and quality. Our team is dedicated to supporting clinical research and trials with tailored solutions, robust analytics, and seamless execution to address the most pressing needs in the industry.
About Axtria's Products and Solutions
Axtria is proud to work with 16 of the top 20 life sciences companies, globally. From our roots as a trusted consultant to our status as one of the world's leading providers of cloud-based pharmaceutical management software, Axtria powers digital transformations in life sciences. Our experts call upon years of domain experience in the industry to guide pharma giants from brand launches to retirement. Our products go even further. Axtria InsightsMAx(TM) helps everyone from the C-suite to junior associates uncover trends to make better decisions. Axtria SalesIQ(TM) helps optimize field forces and provider engagements. Axtria CustomerIQ(TM) leverages AI-enabled next-best-action omnichannel choices. Axtria MarketingIQ(TM) turns investment analyses into pinpoint strategies. And Axtria DataMAx(TM) and DataMAx(TM) for Emerging Pharma is the data management framework that pulls it all together with best-in-class security and integration.
About Axtria
Axtria helps life sciences companies harness the potential of data science and software to improve patient outcomes by connecting the right therapies to the right patients at the right time. The company is a leading global provider of award-winning cloud software and data analytics to the life sciences industry. We're proud to deliver proven solutions that help pharmaceutical, medical device, and diagnostics companies complete their journey from data to insights to action, enabling them to earn superior returns on their investments. As a participant in the United Nations Global Compact, Axtria is committed to aligning strategies and operations with universal principles on human rights, labor, environment, and anti-corruption, and taking actions that advance societal goals. For more information, please visit www.axtria.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/axtria-harnesses-genai-to-slash-timelines-and-boost-accuracy-in-clinical-study-reporting-with-axtria-rapid-csr-302366674.html
SOURCE Axtria, Inc.
|
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
Buyers Edge Platform Appoints Jaime Selga to Lead Expansion Across the Middle East, Africa & Asia | Jan 22, 2026
|
|
Tax Preparation Software Market to Reach $17.6 billion by 2024 in the short term and $43 billion by 2034 Globally, at 9.2% CAGR: Allied Market Research | Jan 22, 2026
|
|
|
|
